Representative before the EPO

Employment test 51 - 200 employees
Company dna mewburn ellis llp
operating since 1890
Headquarter in London and 4 offices
active in Legal Services

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 8 EP applications Catherine Sampson has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP14719739

MUTANT BACTERIA FOR PRODUCTION OF GENERALIZED MODULES FOR MEMBRANE ANTIGENS

IPC classification:
A61K 35/00, A61K 39/095, A61K 39/108, A61K 39/385, C07K 14/285
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Catherine Sampson, GlaxoSmithKline S.A.
Status:
EXAMINATION REQUESTED
EP15192029

ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE

IPC classification:
A61K 39/00, A61K 39/095, G01N 30/02, G01N 33/53, G01N 33/548, G01N 33/569, G01N 33/66
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Catherine Sampson, GlaxoSmithKline S.A.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11736500

LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY

IPC classification:
A61K 9/127, A61K 39/00, C12N 15/86
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Carpmaels & Ransford LLP
Agent:
Multiple attorneys, GlaxoSmithKline
Agent:
Catherine Sampson, GlaxoSmithKline S.A.
Status:
PATENT GRANTED
EP14799018

SALMONELLA CONJUGATE VACCINES

IPC classification:
A61K 47/48, A61P 31/04
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Catherine Sampson, GlaxoSmithKline S.A.
Status:
EXAMINATION REQUESTED
EP14806633

PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS BY GLYCOPROTEIN VACCINES SYNTHESIZED IN ESCHERICHIA COLI

IPC classification:
A61K 39/085
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Catherine Sampson, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15711523

MUTANT STAPHYLOCOCCAL ANTIGENS

IPC classification:
A61K 39/00, A61K 39/085, A61K 39/39, C07K 14/31
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Catherine Sampson, GlaxoSmithKline S.A.
Status:
EXAMINATION REQUESTED
EP17160320

PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR SACCHARIDES

IPC classification:
A61K 39/085, A61K 39/385
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Catherine Sampson, GlaxoSmithKline
Status:
Request for examination was made
EP15813733

METHOD OF TREATMENT

IPC classification:
A61K 39/085
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Catherine Sampson, GlaxoSmithKline S.A.
Status:
Request for examination was made

Please Sign in to use this feature